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We describe direct effects of strontium ranelate on the interaction of osteoblastic cells with different titanium
substrates. Our goal was to better understand the potential of this drug for improving the efﬁcacy of bone implants.
Treatment was done with 0.12 and 0.5 mM Sr2C of strontium ranelate in cell culture. We analyzed cell response to the
drug on titanium substrates with surface topographies obtained using acid etching, electro-erosion processing,
sandblasting, and machine-tooling. Treatment preserved the initial cell adhesion to the substrates, cell shape
parameters (area, aspect ratio, circularity, and solidity), and the orientation of cells on grooved surfaces. However, both
concentrations of the drug increased cell proliferation in all substrates. Moreover, a dose-dependent increase in alkaline
phosphatase activity and in the production of mineralized matrix with typical features of bone tissue was shown. The
observed effects were similar in the different substrates. In conclusion, strontium ranelate improved the interaction of
osteoblastic cells with titanium substrates, increasing cell proliferation and differentiation into mature osteoblasts and
the production of bone-like mineralized matrix for all substrates. This study highlights a promising role of strontium
ranelate on enhancing the clinical success of bone implants, particularly in patients with osteoporosis.
Introduction
The clinical success of bone implants is highly dependent on
the proper integration of the biomaterial into the regenerated
bone tissue. This integration occurs through the adhesion, prolif-
eration, and differentiation of osteoblastic cells followed by the
production of mineralized matrix directly on the surface of the
biomaterial.1-4 Many strategies can be used aiming to improve
implant osseointegration. A promising strategy on the material
side is the manipulation of the surface characteristics of implants,
which allows creating a variety of surface topographies that can
enhance cell and tissue responses.2,5,6 In particular, materials with
grooved surfaces seem to be of interest because they induce contact
guidance of the cells (i.e., cells tend to align in the direction of the
grooves), which may have positive effects on bone growth.7,8
A particular strategy to improve implant osseointegration is
the association of biomaterials with molecules involved in osteo-
blastic cell adhesion, proliferation, and/or differentiation, aiming
to enhance the interaction of cells with the biomaterial and thus
the quality of the tissue/material interface.1,9-11 Among these
molecules, members of the bone morphogenic protein (BMP)
family, such as BMP-2 and BMP-7, are of special interest because
they can stimulate osteoblastic cell differentiation and promote
bone tissue formation.12-14
Strontium ranelate is a promising drug used for treating post-
menopausal osteoporosis. It has a unique dual mode of action,
simultaneously increasing bone formation by osteoblasts and
decreasing bone resorption by osteoclasts, thus improving bone
strength.15-17 In cell cultures, strontium ranelate increased osteo-
blastic cell proliferation,18,19 differentiation,20,21 and the produc-
tion of mineralized nodules.21,22 In postmenopausal women with
osteoporosis, long-term treatment reduced the risk of nonverte-
bral, hip, and vertebral bone fractures.23,24 Moreover, systemic
administration of strontium ranelate enhanced the volume and
microarchitecture of the bone tissue surrounding implants,
improving implant fixation and osseointegration.25-27 Further
studies are necessary to better understand the potential of stron-
tium ranelate for improving the efficacy of bone implants.
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The goal of this study was to evaluate direct effects of stron-
tium ranelate on the interaction of osteoblastic cells with differ-
ent titanium substrates. In particular, we investigated effects on
cell adhesion, proliferation, and differentiation into mature
osteoblasts and on the production of bone-like mineralized
matrix on substrates with different surface topographies, obtained
using acid etching (TAN), electro-erosion processing (TE0N),
sandblasting (TS0N), and machine-tooling (TU0N) (Figs. 1A-
D). We also analyzed cell shape and the orientation of cells on
grooved surfaces. The results of this study highlight a promising
role of strontium ranelate for improving the clinical success of
bone implants, particularly in patients with osteoporosis.
Results
In all analyzed conditions, cells were well adhered and
spread on the different substrates after 24 hours in culture,
often presenting a stellate shape with distinct prolongations
(Figs. 2A–L). Further analysis showed no significant differen-
ces in morphological parameters of the cells (area, aspect
ratio, circularity, and solidity) between control and treated
samples in any of the substrates (Figs. 3A–D). Moreover, on
TU0N substrates, cells were preferentially aligned with the
direction of the grooves, with a similar distribution seen in
control and treated samples (Figs. 4A–C).
The number of cells adhered after 4 hours showed no signifi-
cant differences between control and treated samples in any of
the substrates (Fig. 5A). After 24 hours, however, we noticed a
significant increase in the number of cells in treated samples com-
pared with control in TAN and TE0N substrates (Fig. 5B),
reflecting an increase in the initial proliferation of the cells.
Further analysis showed that strontium ranelate not only had
no toxic effects on the cells, but significantly increased cell prolifer-
ation rates in both treated samples on all substrates, particularly
from 7 to 21 days in culture (Figs. 6A–D). Treatment with both
concentrations of the drug increased cell proliferation quite consis-
tently after 7 days in cultures. After 21 days, however, this increase
was less consistent: in TAN substrates, only cells treated with
0.12 mM Sr2C showed an increase; in TE0N, an increase was only
seen on cells treated with 0.5 mM Sr2C; and in TS0N and TU0N,
both concentrations of the drug increased cell proliferation.
The alkaline phosphatase (ALP) activity of treated cells had
significantly higher values in all substrates (Figs. 7A-D), indicat-
ing an increase in the differentiation of the cells into mature
osteoblasts. This increase was especially marked after 21 days in
culture, occurring mostly in a dose-dependent manner.
An extensive mineralized matrix was formed in all analyzed
conditions after 28 days in culture, presenting typical mineral-
ized nodules that were readily stained with Alizarin red
(Figs. 8A–L). By simple visual inspection, we noticed that this
matrix seemed more developed in treated samples, especially in
those treated with 0.5 mM Sr2C. Quantification of Alizarin red
extracted from the stained cultures confirmed that the drug
induced a significant dose-dependent increase in the formation
of mineralized matrix in all substrates (Fig. 9A). We also found
that the concentration of calcium left in the medium after culture
of treated samples was significantly reduced in all substrates
(Fig. 9B), which is in agreement with the increase in deposition
of calcium phosphate minerals in the matrix.
The mineralized matrix produced in all analyzed conditions
presented similar bone-like characteristics. Typically, we saw
well-developed cell layers along with numerous globular accre-
tions associated with an extensive mesh of randomly oriented
fibrils (Fig. 10A), as often seen in the newly formed native bone.
Analysis of the matrix by Fourier transform infrared spectroscopy
(FTIR) confirmed its bone-like nature, showing bands of PO4
3¡
and CO3
2¡ from the carbonated apatite mineral and of Amide I
and II from the organic matrix proteins (Fig. 10B).
Discussion
Strontium ranelate was shown to improve the osseointegration
of titanium implants in vivo.25-27 In these studies, the authors
evaluated the surrounding bone by micro-CT and biomechanical
testing. However, they did not analyze the cellular components
of the bone/implant interactions. Because of the dual mode of
action of strontium ranelate,15-17 it is difficult to assess in these
Figure 1. Scanning electron micrographs of the pure titanium substrates.
The different surface topographies were obtained by using: (A) acid etch-
ing (TAN), (B) electro-erosion processing (TE0N), (C) sandblasting (TS0N),
and (D) machine-tooling (TU0N). Note the parallel grooves on the TU0N
substrates. Scale bar: 25 mm.
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in vivo studies if the obtained results were directly related to an
increase in bone formation. In our study, using an in vitro osteo-
blastic cell culture system, we provide evidence of a direct effect
of strontium ranelate in the interaction of osteoblastic cells with
biomaterials with different topographies, presenting new data on
how this drug may act on improving implant osseointegration.
We show that treatment with strontium ranelate has clear posi-
tive effects on the behavior of osteoblastic cells cultured on differ-
ent titanium substrates, increasing cell proliferation and
differentiation into mature osteoblasts and the production of
bone-like mineralized matrix. This study is of value to better
understand the promising role of strontium ranelate for improv-
ing the efficacy of bone implants.
The first interaction of cells with biomaterials occurs through
the attachment, adhesion, and spreading of the cells on the sur-
face of the material, which will subsequently influence cell prolif-
eration and differentiation.1 One way of accessing the quality of
this interaction is by analyzing cell shape. In this study, we found
that strontium ranelate induced no changes in morphological
parameters of the cells, preserving a normal first interaction of
the osteoblastic cells with the substrates. Moreover, no changes
were found in the orientation of cells in the grooved substrates,
Figure 2. Fluorescence micrographs of cells labeled with FITC-phalloidin and DAPI. Cells were cultured for 24 hours. The actin cytoskeleton is shown in
green and the nuclei in blue. The cells were well adhered and spread in all analyzed conditions. They often presented a stellate shape with distinct pro-
longations. Scale bar: 50 mm.
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indicating that the drug also preserves the contact guidance
induced by this type of material.8
We saw no differences in the initial adhesion of the cells to the
substrates. We did, however, found that strontium ranelate
increased cell proliferation rate in all substrates, indicating that
treatment may facilitate the development of osteoblastic cell
layers directly on the surface of biomaterials. This improvement
in surface colonization by bone-forming cells may be seen as an
important step toward the integration of the biomaterial into the
regenerated bone tissue.3,4
Figure 3. Analysis of the cell morphology. Individual cells labeled with FITC-phalloidin were analyzed with the ImageJ software after 24 hours in culture.
The morphological parameters analyzed were: (A) cell area, (B) cell aspect ratio, (C) cell circularity, and (D) cell solidity. No signiﬁcant differences were
seen between control and treated samples in any substrate.
Figure 4. Analysis of cell orientation on TU0N substrates. Individual cells labeled with FITC-phalloidin were analyzed with the ImageJ software after
24 hours in culture. Alignment of the cells with the parallel grooves of TU0N substrates was quantiﬁed from 0 (perfectly aligned) to 90 (exactly perpen-
dicular). In control and treated samples, the cells were preferentially aligned with the direction of the grooves, presenting a similar distribution.
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Strontium ranelate increased cell differentiation into mature
osteoblasts, as seen by the marked increase in ALP activity in all
substrates. A high ALP activity is one of the most typical markers
of a more mature, matrix-synthesising osteoblastic phenotype.28
This enzyme is especially related to initial phases of matrix miner-
alization. It functions both by increasing the local concentration
of inorganic phosphate available to bone mineral deposition and
by decreasing that of extracellular pyrophosphate, an inhibitor of
mineral formation, thus promoting matrix mineralization.29
Indeed, we found that strontium ranelate promoted the for-
mation of mineralized matrix in all substrates. Moreover, this
matrix had a typical bone-like nature, resembling that of a newly
formed woven bone tissue.30,31 Such increase is in accordance
with in vivo studies, in which strontium ranelate treatment led to
an improvement in volume and microarchitecture of the new
bone tissue formed around titanium implants, increasing thus
implant osseointegration.25-27
Different substrates were used to provide an overall analysis of
the influence of strontium ranelate on cell behavior, allowing us
to show the effects of treatment in different experimental condi-
tions. When treated with strontium ranelate, the cells cultured
on the biomaterials showed an increased proliferation rate, differ-
entiation into mature osteo-
blasts, and production of
mineralized matrix. These
changes in the behavior of
the osteoblastic cells were
seen in all the substrates we
used, indicating that stron-
tium ranelate had a similar
Figure 6. Cell proliferation
assay. Live cells were moni-
tored over time with the
PrestoBlue Cell Viability
Reagent. An increase in cell
proliferation was seen in
both treated samples in all
substrates, particularly from
day 7 to 21. After 7 days, this
increase was quite consistent
for both concentrations of
the drug. In some cases, an
increase in proliferation was
seen only in cells treated
with either 0.12 or 0.5 mM
Sr2C. A large effect size was
found for the increase seen
on all the substrates (r > 0.5).
*P < 0.05 vs. control.
Figure 5. Analysis of the number of cells adhered on the substrates. The
nuclei labeled with DAPI were counted with the ImageJ software in
images taken using a 10£ objective lens. (A) After 4 hours in culture, no
signiﬁcant differences were found between control and treated samples
in any substrate. (B) After 24 hours, the number of cells in treated sam-
ples was higher than in control in TAN and TE0N substrates, suggesting
an increase in the initial cell proliferation. This increase showed a
medium effect size on both substrates (r  0.3–0.5). *P < 0.05 vs.
control.
www.tandfonline.com e1027847-5Biomatter
effect in cells cultured on the titanium substrates with 4 different
surface topographies. Indeed, the overall magnitude of the
observed effects was similar among the substrates, showing that
surface topography did not modulate the effects of strontium
ranelate on cell behavior.
These results highlight a potential of strontium ranelate for
improving the efficacy of orthopedic implants and bone tissue
engineering approaches. The direct effects of the drug on
enhancing the formation of bone tissue on the surface of bio-
materials may play a relevant role on creating a proper cell/
matrix/material interface to the integration of the biomaterial
into the regenerated tissue.1,2 In this context, we can speculate
that this effect of strontium ranelate could be particularly ben-
eficial to patients with osteoporosis, in which the osseointegra-
tion of bone implants is quite inadequate.32-34 For instance,
in cases in which patients with osteoporosis suffer bone frac-
tures and need bone implants, treatment with strontium rane-
late can be useful not only to prevent further fractures, but
also to help to overcome some negative effects of osteoporosis
on the clinical success of the implants. This reasoning is in
agreement with previous findings described in ovariectomized
rats.25
Figure 7. Cell differentiation assay. ALP activity was analyzed in the cell culture medium by quantifying the hydrolysis of pNPP to pNP/min/mg of total
protein. A clear increase in ALP activity was seen in treated samples in all substrates, especially after 21 days, indicating an increase in the differentiation
of cells into mature osteoblasts. This observed increase showed a large effect size on all the substrates (r > 0.5). *P <0.05 vs. control. yP < 0.05 vs.
0.12 mM Sr2C.
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Finally, it is important to consider the doses of strontium
ranelate used in the present study. The dose of 0.12 mM Sr2C
was chosen based on the Sr2C levels found in the blood serum of
postmenopausal women with osteoporosis treated with 2g of oral
strontium ranelate per day for 3 years.35 The dose of 0.5 mM
Sr2C was used to access a dose effect of the drug. The dose effect
on cell proliferation was quite variable. For instance, for different
times in culture or substrates, we could find an increase in prolif-
eration in both treated samples or only in those treated with
either 0.12 or 0.5 mM Sr2C. On the other hand, a dose-depen-
dent effect was typically seen in cell differentiation and in the
production of mineralized matrix, with a marked increase often
found even after treatment with 0.12 mM Sr2C.
Some limitations of this study should also be considered. For
instance, the murine F-OST cells used in this study were chosen
because of their typical osteoblastic features, including the ability
to produce a bone-like mineralized matrix in culture.36,37
Although the use of this cell allowed evaluating different effects
of strontium ranelate on the interaction of osteoblastic cells with
titanium substrates, these effects should also be analyzed using
human osteoblasts. Moreover, it would be interesting to analyze
how the drug affects osteoblasts derived from osteoporotic bone
Figure 8. Fluorescence micrographs of the mineralized matrix stained with Alizarin red. Cells were cultured under mineralizing conditions for 28 days.
Typical mineralized nodules were observed in all analyzed conditions. They seemed more developed in the treated samples, especially in those treated
with 0.5 mM Sr2C. Scale bar: 100 mm.
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instead of from healthy bone. The presence of osteoclasts in the
cell culture systems would also be valuable to analyze a combined
effect of the drug on bone formation and resorption on the sur-
face of biomaterials.
A point that should also be considered is that treatment
with strontium ranelate is known to lead to the incorporation
of Sr2C into the forming bone mineralized matrix.38,39 This
incorporation occurs with Sr2C partially replacing Ca2C in the
apatite crystal lattice, which can cause several changes in the
composition and crystal structure of the bone mineral.40,41
For this reason, it may be relevant to evaluate in further stud-
ies possible changes caused by strontium ranelate in the quality
of the interaction between the mineralized matrix and the bio-
material surface at the bone apatite crystal level (i.e., at the
nanoscale).
Conclusions
Strontium ranelate improved the interaction of osteoblastic
cells with different titanium substrates. We show that treatment
preserved cell shape and the orientation of cells on grooved sur-
faces, with no changes found also in the initial cell adhesion to
the substrates. We found, however, that treatment increased
cell proliferation and differentiation into mature osteoblasts
and the production of bone-like mineralized matrix in all sub-
strates. The overall magnitude of these effects was similar
among the different substrates. Finally, our results indicate that
strontium ranelate may improve implant osseointegration by
acting directly on osteoblastic cells, playing a promising role on
enhancing the clinical success of bone implants, particularly in
patients with osteoporosis.
Materials and methods
Titanium substrates
The substrates were made of pure tita-
nium and had 4 different surface topogra-
phies, obtained using acid etching (TAN),
electro-erosion processing (TE0N), sand-
blasting (TS0N), and machine-tooling
(TU0N). All substrates had similar rough-
ness amplitudes (Sa D 0.7 mm). In partic-
ular, the TU0N substrates presented
parallel grooves for analyzing contact
guidance of the cells. Scanning electron
micrographs of each of the surfaces were
taken with a FEI Quanta 400 microscope
(Figs. 1A-D). A detailed characterization
can be found elsewhere.42,43
Cell culture
The cells used in this study were F-
OST osteoblasts, previously isolated from
the femoral endosteal region of
Figure 9. Quantiﬁcation of the mineralized matrix. (A) The extraction of
Alizarin red from the stained samples showed a marked dose-dependent
increase in the formation of mineralized matrix in all substrates. (B) The
concentration of calcium left in the medium after culture was clearly
lower in treated samples in all substrates. This is in accordance with the
increase of calcium phosphate minerals deposited on the matrix. This
increase in mineralization showed a large effect size on all the substrates
(r > 0.5).*P < 0.05 vs. control. yP < 0.05 vs. 0.12 mM Sr2C.
Figure 10. Typical characteristics of the bone-like matrix produced in all analyzed conditions. (A)
Scanning electron micrograph. The well-developed cell layers were seen along with numerous glob-
ular accretions (see arrows in the inset) associated with an extensive mesh of randomly oriented
ﬁbrils (see asterisks in the inset). (B) FTIR spectra. Note bands of PO4
3¡ and CO32¡ from the carbon-
ated apatite mineral and of Amide I and II from the organic matrix proteins. Scale bar: (a) 10 mm;
(inset) 2 mm.
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8–12 weeks old male BALB/c mice38 and cryopreserved in liquid
nitrogen to be used in future studies. They present high alkaline
phosphatase (ALP) activity, produce typical bone matrix proteins
(e.g., type I collagen, bone sialoprotein, and osteopontin), and
spontaneously form mineralized nodules under basal culture con-
ditions.36 The matrix produced by these cells in culture show
many typical bone-like characteristics.37 The cells were seeded
onto the titanium substrates at a density of 2.0 £ 104 cells/sam-
ple in 24-well plates. Before placing the substrates in the plates,
the wells were coated with a 2% agar gel to avoid cell adhesion
on their bottom. Cells were cultured in Dulbecco’s Modified
Eagle Medium containing 10% fetal bovine serum and antibiot-
ics (100 U/mL of penicillin and 100 mg/mL of streptomycin).
For the mineralization assay, cells were cultured in medium with
50 mg/mL of ascorbic acid and 2 mM of b-glycerophosphate.
The medium was changed twice a week. Cells were treated dur-
ing the whole culture time with strontium ranelate (PROTOS

2g, Servier) added to the medium at 0.12 and 0.5 mM Sr2C.
The control used for each of the titanium substrates were cell cul-
tures that were not treated with strontium ranelate.
Fluorescent labeling of the cells
After culture, samples were fixed with 2% paraformaldehyde
for 30 min, permeabilized with 0.2% Triton X-100 for 15 min,
and incubated with 1% albumin solution for 20 min to block
nonspecific protein binding sites. The samples were then incu-
bated with 0.4 mg/mL of FITC-phalloidin for 60 min to label
the actin cytoskeleton of the cells and with 100 ng/mL of DAPI
for 20 min to label the cell nuclei. After each of the described
steps, samples were washed 3 times with phosphate buffered
saline (PBS). The labeled cells were observed with an Olympus
BX51 epifluorescence microscope.
Image analysis
Fluorescence images were analyzed with the ImageJ software
(version 1.47v).44 In order to evaluate the shape of cells, we care-
fully traced the outlines of individual cells labeled with FITC-
phalloidin after 24 hours in culture and measured their area and
shape descriptors – aspect ratio, circularity, and solidity. Briefly,
the aspect ratio is calculated as the major/minor axes of the best
fitting ellipse, with values increasing from 1.0 indicating an elon-
gation of the cells. Circularity is obtained by calculating 4p £
area/perimeter2, with a value of 1.0 indicating a perfect circle.
Solidity is the area/(convex area), showing values decreasing from
1.0 in cells with irregular shapes and distinct prolongations.
To analyze the orientation of the cells, we measured the small-
est angle between the major axis of their best fitting ellipse and
the direction of the grooves in TU0N substrates, obtaining values
ranging from 0 (perfectly aligned) to 90 (exactly perpendicu-
lar). At least 60 individual cells were examined for each analyzed
condition. The number of cells on the substrates after 4 and
24 hours in culture was determined by counting the nuclei
labeled with DAPI per field using a 10£ objective lens. At least
30 fields were examined for each analyzed condition.
Cell proliferation
Cells were analyzed after 1, 4, 7, 14, and 21 days with the
PrestoBlue

Cell Viability Reagent (Life Technologies). This
reagent is a resazurin-based solution that allows monitoring living
cells over time and quantitatively measure their proliferation.
Briefly, cells were incubated with the PrestoBlue solution for
60 min at 37C in the dark. The solutions were then collected
and the absorbance was measured at 570 nm with 595 nm as a
reference wavelength using a microplate reader. Each sample was
analyzed in triplicate.
Cell differentiation
Osteoblastic cell differentiation was investigated after 7, 14,
and 21 days by measuring the ALP activity in the cell culture
medium. Samples were analyzed using p-nitrophenyl phosphate
(pNPP) as a colorimetric substrate for ALP. Briefly, samples were
incubated with 1 mg/mL of p-NPP in 1 M diethanolamine
buffer for 10 min and absorbance was measured at 405 nm using
a microplate reader. Each sample was analyzed in triplicate.
Standards were used to determine the concentration of p-nitro-
phenol (pNP, product of pNPP hydrolysis) and Coomassie
Plus
TM
(Bradford) Assay Kit (Thermo Scientific Pierce) was used
for total protein quantitation. Results were expressed as nmol of
pPN produced per min per mg of protein.
Alizarin red staining and quantification
Cells were cultured with mineralizing medium for 28 days,
fixed with 2% paraformaldehyde for 30 min, and washed with
PBS. They were then stained with a 2% Alizarin red solution for
10 min and washed extensively with distilled water. Images of
the mineralized matrix were taken with an Olympus BX51 epi-
fluorescence microscope. The mineralized matrix was quantified
by extracting the Alizarin red from the samples using cetylpyridi-
nium chloride (CPC). Briefly, the stained samples were incu-
bated with 10% w/v CPC in 10 mM sodium phosphate buffer
under sonication for 3 hours. The solutions were then collected
and the solubilized Alizarin red was quantified by measuring the
absorbance at 550 nm using a microplate reader. Each sample
was analyzed in triplicate.
Quantification of calcium in the medium
At the end of the 28 days of the mineralization assays, the cell
culture medium was collected and analyzed using an arsenazo III
method with the Calcium AS FS kit (DiaSys Diagnostic Systems)
to quantify the concentration of calcium left in the medium after
culture. This was done to indirectly assess the amount of calcium
deposited in the mineralized matrix. Briefly, samples were incu-
bated with the reagent for 5 min and absorbance was measured
at 650 nm using a microplate reader. The absorbance values
were adjusted to mg/mL of calcium using a standard solution
curve. Each sample was analyzed in triplicate.
Scanning electron microscopy
After 28 days in culture, the mineralized samples were fixed
with 4% glutaraldehyde and 2% paraformaldehyde in 0.1 M
phosphate buffer for 30 min and washed 3 times with PBS.
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They were then dehydrated in increasing ethanol solutions (50,
70, 80, 95, and 100%), with 3 5-min baths per solution. Hexam-
ethyldisilazane (HMDS) was used for drying the samples.
Finally, the samples were sputter coated with gold and observed
by scanning electron microscopy (SEM) with a FEI Quanta
400 microscope.
Fourier transform infrared spectroscopy
Before the gold coating, the samples described above for SEM
were analyzed by Fourier transform infrared spectroscopy (FTIR)
with a Bruker IFS 66/S spectrometer combined to a Bruker
IRScope-1 microscope. Absorption spectra were acquired by
averaging 128 scans at a resolution of 4 cm¡1 using the attenu-
ated total reflection (ATR) mode, which allows analyzing samples
directly without damaging them.
Statistical analyses
Statistical analyses were carried out using the SPSS

Statistics
software (version 20; IBM). Data are presented as mean § 95%
confidence interval. Kruskal-Wallis test (nonparametric
ANOVA) was used for the overall comparison among the control
and treatment groups. In cases in which we found a significant
difference, we further compared each treatment group with the
control using the Mann-Whitney test. Differences were consid-
ered significant when P < 0.05. In order to compare the magni-
tude of the effects of strontium ranelate seen on the different
substrates, we measured the effect size r, considering the stan-
dardized estimates of r > 0.5 for a large effect, r0.3–0.5 for a
medium effect, and r < 0.3 for a small effect.45,46
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